SPY enters September with one of its cleaner reversals of the past month: the extreme defensive positioning that defined late August has unwound almost entirely, even as the ETF dips modestly from its record highs.
The most striking change is in options. The prior note flagged a PCR of 2.4783 on August 25 — a fresh 52-week extreme, running more than two standard deviations above its 20-day mean, with put buyers pressing harder week after week. That setup has now fully reversed. The PCR closed at 2.03 on September 1, almost exactly in line with its 20-day average of 2.04 and carrying a z-score of just -0.04 — statistically neutral. The 52-week high remains 2.40, set just days ago, which makes the speed of the unwind notable. Put demand did not fade gradually; it dropped sharply once the late-August anxiety eased. The 52-week low of 1.27 shows how much structural hedging demand this market carries even in calm periods, so a reading of 2.03 still reflects a defensively tilted investor base — just not an alarmed one.
Short interest is a secondary story this week, and a mildly constructive one. Shorts covering has been the trend over the past month, with the borrowed share count down roughly 4% over 30 days to around 92.5 million shares, or about 9% of float. That 30-day drift lower is consistent with what the prior note described — a short base quietly shrinking — and it has continued. The one-week picture shows a small uptick of around half a percent, which looks like noise rather than a conviction rebuild. The borrow market remains loose. Availability is running at nearly 870% — meaning almost nine shares are available to borrow for every one already out on loan — well above the 52-week tightest point of 34%. Cost to borrow has ticked up about 40% on the week to 0.40%, which sounds dramatic in percentage terms but is trivial in absolute terms; 0.40% annualised is an extremely cheap borrow for any name. The lending market is not signalling stress.
The institutional holder list adds some texture to the August flow picture. Jane Street added roughly 24 million shares in the quarter to June 30, making it the second-largest disclosed holder at about 4.4% of shares. D.E. Shaw nearly doubled its position, adding 13.3 million shares to reach 1.4% of the float. On the other side, Morgan Stanley trimmed by 8.1 million shares and Goldman Sachs cut by 4.3 million. The pattern — market-makers and quant funds building, bank broker-dealers trimming — is consistent with hedging demand rising through the period, as dealers warehouse inventory to facilitate put activity. The fact that Jane Street and D.E. Shaw were both significant buyers while the PCR was climbing is structurally coherent.
The ORTEX short score edged up to 46.4 on September 1 from around 43.5–44 over the prior two weeks — a mild increase, though the score remains well inside neutral territory and below the 50 threshold that would flag genuine short-side pressure. It moved in tandem with the one-day uptick in borrowed shares rather than ahead of it, suggesting it is tracking the data rather than leading it.
What to watch now is whether the PCR stabilises near its 20-day average or re-escalates. The prior cycle saw put demand climb for nearly two straight weeks before peaking — if macro catalysts emerge through September, the reset to neutral could prove short-lived.
See the live data behind this article on ORTEX.
Open SPY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
